Int J Urol. 2006 Jun;13(6):834-7.

Progress report on phase I/II clinical trial of Ad-OC-TK plus VAL therapy for metastatic or locally recurrent prostate cancer: Initial experience at Kobe University.

Hinata N, Shirakawa T, Terao S, Goda K, Tanaka K, Yamada Y, Hara I, Kamidono S, Fujisawa M, Gotoh A.

Source

Division of Urology, Department of Organ Therapeutics, Faculty of Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.

Abstract

There is no effective therapy for hormone-refractory prostate cancer and a novel therapeutic modality, such as a gene therapy, should be actively pursued. Previously, Gardner and Chung conducted a phase I clinical trial of Ad-OC-TK (recombinant adenoviral vector containing osteocalcin promoter-driven herpes simplex virus thymidine kinase gene) plus VAL (valacyclovir) for the treatment of hormone-refractory prostate cancer at the University of Virginia. We report on our ongoing phase I/II clinical trial of Ad-OC-TK plus VAL for the treatment of advanced prostate cancer at the Kobe University Hospital, Japan.

PMID:: 16834676; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Full Text Sources

Medical

Molecular Biology Databases

ACYCLOVIR - HSDB

Supplemental Content

Save items

Related citations in PubMed

Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer. [Hum Gene Ther. 2007]
Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer.
Shirakawa T, Terao S, Hinata N, Tanaka K, Takenaka A, Hara I, Sugimura K, Matsuo M, Hamada K, Fuji K, et al. Hum Gene Ther. 2007 Dec; 18(12):1225-32.
Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. [Hum Gene Ther. 2003]
Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoter-driven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer.
Kubo H, Gardner TA, Wada Y, Koeneman KS, Gotoh A, Yang L, Kao C, Lim SD, Amin MB, Yang H, et al. Hum Gene Ther. 2003 Feb 10; 14(3):227-41.
Osteocalcin-directed gene therapy for prostate-cancer bone metastasis. [World J Urol. 2000]
Osteocalcin-directed gene therapy for prostate-cancer bone metastasis.
Koeneman KS, Kao C, Ko SC, Yang L, Wada Y, Kallmes DF, Gillenwater JY, Zhau HE, Chung LW, Gardner TA. World J Urol. 2000 Apr; 18(2):102-10.
Review [Gene therapy]. [Hinyokika Kiyo. 2005]
Review [Gene therapy].
Gotoh A, Shirakawa T, Wada Y, Hinata N, Terao S, Hara I, Arakawa S, Kamidono S, Okada H, Takenaka A, et al. Hinyokika Kiyo. 2005 Feb; 51(2):75-9.
Review INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201. [Drugs R D. 2007]
Review INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
. Drugs R D. 2007; 8(3):176-87.

See reviews... See all...

Cited by 1 PubMed Central article

A method for quantification of nucleotides and nucleotide analogues in thymidine kinase assays using lanthanum phosphate coprecipitation. [Anal Biochem. 2007]
A method for quantification of nucleotides and nucleotide analogues in thymidine kinase assays using lanthanum phosphate coprecipitation.
Gammon ST, Bernstein M, Schuster DP, Piwnica-Worms D. Anal Biochem. 2007 Oct 1; 369(1):80-6. Epub 2007 Jun 15.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Progress report on phase I/II clinical trial of Ad-OC-TK plus VAL therapy for me...
Progress report on phase I/II clinical trial of Ad-OC-TK plus VAL therapy for metastatic or locally recurrent prostate cancer: Initial experience at Kobe University.
Int J Urol. 2006 Jun ;13(6):834-7.

PubMed
Cloning of large isoform of human brain glutamic acid decarboxylase.
Cloning of large isoform of human brain glutamic acid decarboxylase.
Lancet. 1991 Dec 7 ;338(8780):1468-9.

PubMed
The effect of Benson Relaxation Technique on rheumatoid arthritis patients: exte...
The effect of Benson Relaxation Technique on rheumatoid arthritis patients: extended report.
Int J Nurs Pract. 2006 Aug ;12(4):214-9.

PubMed
Routine HIV testing in Botswana: a population-based study on attitudes, practice...
Routine HIV testing in Botswana: a population-based study on attitudes, practices, and human rights concerns.
PLoS Med. 2006 Jul ;3(7):e261.

PubMed
DNA light on the Tegernsee giant.
DNA light on the Tegernsee giant.
Lancet. 1991 Dec 7 ;338(8780):1454-5.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Progress report on phase I/II clinical trial of Ad-OC-TK plus VAL therapy for metastatic or locally recurrent prostate cancer: Initial experience at Kobe University.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Cited by 1 PubMed Central article

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information